http://orcid.org/0000-0002-3769-9535
Figures & data
Figure 1. Consort diagram.
Table 1. Baseline demographic and clinical characteristics.
Figure 2. Five most common treatment sequences by index asthma maintenance medication group.
Proportions were calculated using the total number of patients across all index therapies as the denominator (n = 55,293); durations above each arrow denote the mean time spent in a given treatment class by patients with that treatment sequence; total sequence durations may not sum to the same value due to rounding and leap years.
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
Figure 3. Survival analysis of time to first change in therapy (days) by index asthma maintenance medication group.
For description of first event, see . Other included leukotriene receptor antagonists (LTRA) and methylxanthines. ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
Table 2. Summary of time to first medication change and therapy change event by index treatment class.
Figure 4. Proportion of patients prescribed ≥ 4 SABD cannisters during baseline and follow-up by index asthma maintenance medication group.
Other included leukotriene receptor antagonists (LTRA) and methylxanthines.
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
Table 3. Asthma maintenance therapies prescribed during 2-year follow-up by index asthma maintenance medication group.
Figure 5. Proportion of patients who had RCP3Q review during follow-up by index asthma maintenance medication group.
Other included leukotriene receptor antagonists (LTRA) and methylxanthines
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
Supplemental Material
Download Zip (260 KB)Availability of data and materials
Information on GSK’s data sharing commitments and requesting access can be found at: https://www.clinicalstudydatarequest.com